Liu Z, Lavine KJ, Hung IH, Ornitz DM
Abbreviations MASLD : Metabolic dysfunction-associated steatotic liver disease MASH : Metabolic dysfunction-associated steatohepatitis T2DM : Type 2 diabetes mellitus GLP-1 RAs : Glucagon-like peptide-1 receptor agonists GIP : Glucose-dependent insulinotropic polypeptide GCG : Glucagon AACE : American Association of Clinical Endocrinology AASLD : American Association for the Study of the Liver Diseases F2 : Fibrosis grade 2 ABCD : Adiposity-based chronic diseases EASO : European Association for the Study of Obesity VAT : Visceral adipose tissue FFA : Free fatty acids HSC : Hepatic stellate cells FDA : Food and drug administration F3 : Fibrosis grade 3 AST : Aspartate aminotransferase ALT : Alanine aminotransferase GGT : Gamma-glutamyl transferase NAFLD : Non-alcoholic fatty liver-disease LFC : Liver fat content MRI-PDFF : Magnetic resonance imaging derived proton density fat fraction ELF : Enhanced liver fibrosis FIB-4 : Fibrosis-4 index F1 : Fibrosis grade 1 NAS : NAFLD activity score AE : Adverse event SAE : Serious adverse event EMA : European Medicine Agency FGF21 : Fibroblast growth factor 21 MetALD : Metabolic dysfunction and alcohol-related liver disease References Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, Lee K, Stave CD, Henry L, Barnett SD, Cheung R, Nguyen MH
J., Knuhtsen S., Baldissera F
The GLP-1 landscape changed in 2026
It reflects: A large population is struggling with metabolic health Increased acceptance of pharmacological tools Shifts in how obesity and weight management are medically framed GLP-1 use among women is not a niche trend
Selenomethionine induction of DNA repair response in human fibroblasts
